Tissue-type plasminogen activator as a therapeutic target in stroke - Wikidata - awgldk - TriplyDB

Tissue-type plasminogen activator as a therapeutic target in stroke

Tissue-type plasminogen activator as a therapeutic target in stroke

http://www.wikidata.org/entity/Q56336828

about

Vascular protection to increase the safety of tissue plasminogen activator for stroke A Novel Canine Model of Acute Vertebral Artery Occlusion Direct Thrombus Imaging in Stroke Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.Brain immune cell composition and functional outcome after cerebral ischemia: comparison of two mouse strains Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke.Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis Neurodegeneration induced by PVC-211 murine leukemia virus is associated with increased levels of vascular endothelial growth factor and macrophage inflammatory protein 1 alpha and is inhibited by blocking activation of microglia Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries.Edaravone, a Synthetic Free Radical Scavenger, Enhances Alteplase-Mediated Thrombolysis.Clinical outcome prediction after thrombectomy of proximal middle cerebral artery occlusions by the appearance of lenticulostriate arteries on magnetic resonance angiography: A retrospective analysis.Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke.Uric acid enhances alteplase-mediated thrombolysis as an antioxidant

P2860

Q26824338-328D3779-0CFA-466D-99FF-DBB96B021044 Q27346520-F323C021-D52E-46D1-92AC-6851CFE9DF93 Q28075966-82F83367-EA77-4A08-8CA8-D5BA4CC2A8FE Q33823616-EA819040-AEF4-463A-9EFF-1F236684A5CF Q34171180-BD7F3488-8199-45DA-A040-F45892923ED2 Q34541068-E4C144D1-95E7-4A22-A52F-1AE5597F6CCC Q35675445-805FEEAE-154E-4480-945E-68014E2D274B Q36351793-34884453-91B4-4C87-B31D-60D6853D618B Q36925788-A8C65C9F-2469-4D24-85AF-2A58E361235C Q36962704-4D0D0052-AF8C-4BF8-8818-31ECC604075D Q37192113-CD5B65F2-FA44-497D-9EFF-B1EBAE8D484B Q39394485-4C856193-271D-4BCB-B8E2-EBA38DF73FEA Q47137226-7CA5BC89-E074-48A6-A90C-375F48542E89 Q47662344-7A5807C6-9E3F-468F-8AFE-6EA9F7024860 Q48558308-2D922B12-CC99-4EED-987F-88F3FD6D817D Q58116221-D8B844E3-3CFC-4427-96D5-081A80CDB529

P2860

Tissue-type plasminogen activator as a therapeutic target in stroke

http://www.wikidata.org/entity/Q56336828

description

article

@en

im Februar 2008 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в лютому 2008

@uk

ലേഖനം

@ml

name

Tissue-type plasminogen activator as a therapeutic target in stroke

@en

Tissue-type plasminogen activator as a therapeutic target in stroke

@nl

type

label

Tissue-type plasminogen activator as a therapeutic target in stroke

@en

Tissue-type plasminogen activator as a therapeutic target in stroke

@nl

prefLabel

Tissue-type plasminogen activator as a therapeutic target in stroke

@en

Tissue-type plasminogen activator as a therapeutic target in stroke

@nl

P1433

Q56336828-77B4DA44-0BE7-4D8A-AC1C-625EBAA78A6B

P1476

Q56336828-C6032DC0-4149-407A-AB41-964555638C83

P2093

Q56336828-08FB7543-813B-42EF-A735-47AA576C8018

Q56336828-B0DD8220-7D93-450F-A7BA-CB271257304B

P2860

Q56336828-065B9E55-A3B9-48F3-9166-5FFD739D8588

Q56336828-0706B66B-E515-4605-A028-306999E8E115

Q56336828-0A343AA6-6678-43D7-91ED-F79B877E1BAE

Q56336828-0BE0F5D8-F117-407F-B3FC-7AA68D91A198

Q56336828-130FD005-B20C-4AC9-89F2-200D8873919D

Q56336828-13A9FFAD-C139-4726-B6E7-BCCD95AE2861

Q56336828-15020340-00C9-422B-8DF4-A8B5969D6D66

Q56336828-16F07587-ABA9-4A31-A7F7-71AA1AEFE1F9

Q56336828-1743647D-950E-4A3B-B902-566C6BDD462C

Q56336828-19B4835A-2BBF-4287-A686-F4B549DCE9DD

P304

Q56336828-D25A4D99-ADA7-4857-A2F3-D14082669B79

P31

Q56336828-1834D9F9-B8AD-4688-B81C-4433AFBB45B6

P356

Q56336828-DD633508-FBDD-445C-98EB-F72ABDBFC8E5

P407

Q56336828-4DC492F4-A601-4BF6-B74C-C066F8C1ED93

P433

Q56336828-C3978E68-47FB-486E-8F97-AB1FB1B376EC

P478

Q56336828-3BCD1C12-3035-480D-83CF-39C8F49AE15F

P577

Q56336828-0A41C3DF-AD4D-49A3-A991-DD920118D389

P698

Q56336828-D18F9C9A-8AB5-405C-B798-9054CB101740

P932

Q56336828-641A1A29-1495-4186-B008-3EA3AF51E0AF

P356

14728222.12.2.159

P1433

Expert Opinion on Therapeutic Targets

P1476

Tissue-type plasminogen activator as a therapeutic target in stroke

@en

P2093

Iordanis Gravanis

http://www.w3.org/2001/XMLSchema#string

Stella E Tsirka

http://www.w3.org/2001/XMLSchema#string

P2860

Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration.

Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor

Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial

Antithrombotic and hypofibrinogenetic therapy in acute ischemic stroke: what is the next step?

Minor inflammation after surgical evacuation compared with fibrinolytic therapy of experimental intracerebral hemorrhages

Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke

Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration

Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I

Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial

Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial

P304

159-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.12.2.159

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18208365

http://www.w3.org/2001/XMLSchema#string

P932

3824365

http://www.w3.org/2001/XMLSchema#string